TherapeuticsMD (TXMD) Given Daily Media Impact Score of 0.18

News coverage about TherapeuticsMD (NASDAQ:TXMD) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.2887401749114 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of research firms recently issued reports on TXMD. Oppenheimer Holdings, Inc. set a $10.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, August 17th. Deutsche Bank AG set a $10.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a report on Friday, August 11th. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target on the stock. BidaskClub raised TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $14.72.

Shares of TherapeuticsMD (NASDAQ TXMD) traded up $0.06 during trading hours on Wednesday, reaching $6.05. 1,945,174 shares of the company were exchanged, compared to its average volume of 2,910,591. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same quarter last year, the firm earned ($0.13) earnings per share. The firm’s revenue was down 19.7% compared to the same quarter last year. equities analysts forecast that TherapeuticsMD will post -0.37 EPS for the current year.

In related news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Wednesday, August 30th. The stock was bought at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares in the company, valued at $21,294.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 23.92% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD (TXMD) Given Daily Media Impact Score of 0.18” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/22/therapeuticsmd-txmd-given-daily-media-impact-score-of-0-18.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply